FrancophonIA/ELRC3.0 huggingface dataset:
English: The daily dose may be divided if it consists of more than one capsule in order to mimic the continuous production of cholic acid in the body and to reduce the number of capsules that need to be taken per administration.
Estonian: Kui ööpäevane annus koosneb mitmest kapslist, võib annuse jaotada mitmeks osaks, et imiteerida koolhappe pidevat tekkimist organismis ja vähendada korraga võetavate kapslite arvu.
English: - The active substance is cholic acid.
Estonian: - Toimeaine on koolhape.
English: Phenobarbital antagonises the effect of cholic acid.
Estonian: Fenobarbitaal on koolhappe antagonist.
English: The dose of bile acid sequestrants or antacids must be separated from the dose of cholic acid by an interval of 5 hours, regardless of which medicinal product is administered first.
Estonian: Sapphapete sekvestrantide või antatsiidide annuse ja koolhappe annuse manustamise vahele peab jääma 5 tundi, sõltumata sellest, mis ravimit manustatakse esimesena.
English: Cholic acid has no or negligible influence on the ability to drive and use machines.
Estonian: Koolhappel ei mõjuta või mõjutab ebaoluliselt autojuhtimise ja masinate käsitsemise võimet.
English: How to take Orphacol
Estonian: Kuidas Orphacoli võtta
English: Orphacol contains cholic acid, a bile acid which is normally produced by the liver.
Estonian: Orphacol sisaldab koolhapet - sapphapet, mis normaalsetes tingimustes tekib maksas.
English: Concurrent elevation of serum gamma glutamyltransferase (GGT), alanine aminotransferase (ALT) and/or serum bile acids above normal levels may indicate overdose.
Estonian: Seerumi gamma-glutamüültransferaasi (GGT), alaniini aminotransferaasi (ALT) aktiivsuse suurenemine ja/või seerumi sapphapete kontsentratsiooni samaaegne suurenemine üle normaalse võib viidata üleannustamisele.
English: Development of gallstones associated with long-term treatment have been reported in very limited number of patients.
Estonian: Väga väikesel arvul patsientidest on teatatud sapikivide tekkest pikaajalise raviga seoses.
English: A small fraction of bile acids is excreted in urine.
Estonian: Väike osa sapphapetest väljutatakse uriiniga.
English: How to store Orphacol
Estonian: Kuidas Orphacoli säilitada
English: The following table lists adverse reactions reported in the literature under treatment with cholic acid.
Estonian: Alljärgnevas tabelis on loetletud kirjanduse põhjal kõrvaltoimed, mis ravi korral koolhappega on kaasnenud.
English: Diarrhoea, increased transaminases and pruritus have been associated with overdosage and disappeared after dose reduction.
Estonian: Üleannustamisega on seostatud kõhulahtisust, transaminaaside aktiivsuse suurenemist ja kihelust, mis möödusid pärast annuse vähendamist.
English: Ciclosporin alters the pharmacokinetics of cholic acid by inhibition of the hepatic uptake and hepatobiliary secretion of bile acids, as well as its pharmacodynamics by inhibition of cholesterol 7α-hydroxylase.
Estonian: Tsüklosporiin mõjutab nii koolhappe farmakokineetikat, pärssides sapphapete imendumist maksas ja hepatobiliaarset eritumist, kui ka farmakodünaamikat, pärssides kolesterooli 7α-hüdroksülaasi.
English: In repeated-dose studies, frequently reported effects of cholic acid have included decreased body weight, diarrhoea and liver damage with elevated transaminases.
Estonian: Kroonilise toksilisuse uuringutes on koolhappe kõrvaltoimetena sageli registreeritud kehakaalu vähenemist, kõhulahtisust ja maksakahjustust koos transaminaaside aktiivsuse suurenemisega.
English: Orphacol is available as hard capsules (capsules) of oblong shape.
Estonian: Orphacol on saadaval piklike kõvakapslitena (kapslitena).
English: Both inborn diseases are extremely rare, with a prevalence in Europe of about 3 to 5 patients with 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency per 10 million inhabitants, and an estimated ten-fold lower prevalence for Δ4-3-Oxosteroid-5β-reductase deficiency.
Estonian: Mõlemad kaasasündinud haigused on väga haruldased: Euroopas on esinemissagedus 10 miljoni elaniku kohta ligikaudu 3...5 patsienti, kellel on 3β-hüdroksü-Δ5-C27-steroidi oksidoreduktaasi puudulikkus, ja Δ4-3-oksüsteroid-5β-reduktaasi puudulikkuse esinemissagedus on hinnanguliselt kümme korda madalam.
English: The exposed pregnancies showed no adverse reactions to cholic acid and resulted in normal, healthy children.
Estonian: Ravi ajal rasestunutel ei täheldatud koolhappest tingitud kõrvaltoimeid ning vastsündinud olid normaalse arenguga ja terved.
English: 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency The daily dose ranges from 5 to 15 mg/kg in infants, children, adolescents and adults.
Estonian: 3β-hüdroksü-Δ5-C27-steroidi oksidoreduktaasi puudulikkus Imikute, laste, noorukite ja täiskasvanute ööpäevane annus on 5…15 mg/kg.
English: The clinical experience reported in the literature is from a patient population with inborn deficiency of 3β-Hydroxy-Δ5-C27-steroid oxidoreductase or Δ4-3-Oxosteroid-5β-reductase that includes principally infants from the age of one month, children and adolescents.
Estonian: Kirjanduses avaldatud kliinilised andmed pärinevad patsiendipopulatsioonist, kellel esineb 3β-hüdroksüΔ5-C27-steroidi oksidoreduktaasi või Δ4-3-oksüsteroid-5β-reduktaasi kaasasündinud puudulikkus ja mis peamiselt hõlmab vähemalt 1-kuuseid imikuid ning lapsi ja noorukeid.
English: A concomitant decrease of urine total bile acids should be observed.
Estonian: Tuleb jälgida kaasneva nähuna esinevat sapphapete üldkontsentratsiooni vähenemist uriinis.
English: Orphacol 250 mg: Each hard capsule contains 250 mg of cholic acid.
Estonian: Orphacol 250 mg: üks kõvakapsel sisaldab 250 mg koolhapet.
English: Please consult your doctor if you plan to become pregnant.
Estonian: Kui te plaanite rasedust, pidage palun nõu oma arstiga.
English: In patients with inborn deficiency of 3β-Hydroxy-Δ5-C27-steroid oxidoreductase and Δ4-3-Oxosteroid-5β-reductase, the biosynthesis of primary bile acids is reduced or absent.
Estonian: 3β-hüdroksü-Δ5-C27-steroidi oksidoreduktaasi või Δ4-3oksüsteroid-5β-reduktaasi kaasasündinud puudulikkusega patsientidel on esmaste sapphapete biosünteesi aktiivsus väike või puudub.
English: Orphacol 250 mg: gelatin, titanium dioxide (E171), carmine blue (E132), yellow iron oxide (E172).
Estonian: Kapslite kate: Orphacol 50 mg: želatiin, titaandioksiid (E171), karmiinsinine (E132); Orphacol 250 mg: želatiin, titaandioksiid (E171), karmiinsinine (E132), raudoksiidkollane (E172).
English: Gallstones have been reported after long-term therapy with Orphacol.
Estonian: Pärast Orphacoli pikaajalist kasutamist on teatatud sapikivide tekkest.
English: Cholic acid showed non-significant mutagenic activity in a battery of genotoxicity tests performed in vitro.
Estonian: Genotoksilisuse in vitro katsed ei näidanud koolhape olulist mutageenset aktiivsust.
English: Orphacol is indicated for the treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency in infants, children and adolescents aged 1 month to 18 years and adults.
Estonian: Orphacol on näidustatud 3β-hüdroksü-Δ5-C27-steroidi oksidoreduktaasi või Δ4-3-oksüsteroid-5β reduktaasi puudulikkusest tingitud sapphapete sünteesi kaasasündinud häirete raviks vähemalt 1 kuu vanustel imikutel, kuni 18-aastastel lastel ja noorukitel ning täiskasvanutel.
English: As a precautionary measure, pregnant women and their unborn children should be closely monitored.
Estonian: Ettevaatuse mõttes tuleb rasedaid ja loodet tähelepanelikult jälgida.
English: Orphacol 50 mg: Each hard capsule contains 50 mg of cholic acid.
Estonian: Orphacol 50 mg: üks kõvakapsel sisaldab 50 mg koolhapet.
English: The available non-clinical data in the literature reveal no special hazard for humans based on studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.
Estonian: Farmakoloogilise ohutuse, korduvtoksilisuse, genotoksilisuse, kartsinogeensuse ja reproduktsioonitoksilisuse mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: The cholic acid dose for patients with familial hypertriglyceridemia will have to be established and adjusted as described, but an elevated dose, notably higher than the 500 mg daily limit for adult patients, may be required and safe.
Estonian: Familiaalse hüpertriglütserideemiaga patsientidel tuleb koolhappe annus kindlaks teha ja kohandada nii, nagu eespool kirjeldatud, kuid sel juhul võib olla vaja suuremat annust, mis ületab märkimisväärselt täiskasvanute maksimaalset annust 500 mg ööpäevas ning on ohutu.
English: Lactose monohydrate, Colloidal anhydrous silica, Magnesium stearate.
Estonian: Kapsli sisu: laktoosmonohüdraat kolloidne veevaba ränidioksiid magneesiumstearaat.
English: Gallstones have been reported after long-term therapy.
Estonian: Pärast pikaajalist ravi on registreeritud sapikivide esinemist.
English: The development of pruritus and/or diarrhoea has been observed during treatment with Orphacol.
Estonian: Orphacoliga ravi ajal on täheldatud kiheluse ja/või kõhulahtisuse esinemist.
English: Overall, cholic acid treatment results for about 60 patients with 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency are reported in the literature.
Estonian: Kokku on kirjanduses avaldatud ligikaudu 60 3βhüdroksü-Δ5-C27-steroidi oksidoreduktaasi puudulikkusega patsiendi koolhappe ravitulemused.
English: The MAH, in agreement with the competent authorities in the Member States, shall implement, prior to the launch, an educational programme for physicians aiming to provide educational material on correct diagnosis and therapeutic managements of the treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency and to inform on expected and potential risks associated with the treatment.
Estonian: Kooskõlas liikmesriikide pädevate asutustega korraldab müügiloa hoidja enne ravimi turule lubamist arstidele koolituse, mille eesmärgiks on tutvustada 3β-hüdroksü-Δ5-C27-steroidi oksidoreduktaasi või Δ4
English: There is a risk of permanently damaging your liver if you stop taking Orphacol.
Estonian: Kui te lõpetate Orphacoli võtmise, on oht, et tekib püsiv maksakahjustus.
English: The dose of cholic acid in such patients should be established and adjusted as described, but an elevated dose, notably higher than the 500 mg daily limit for adult patients, may be required.
Estonian: Neil patsientidel tuleb koolhappe annus kindlaks teha ja kohandada nii, nagu eespool kirjeldatud, kuid sel juhul võib olla vaja suuremat annust, mis ületab märkimisväärselt täiskasvanute maksimaalset annust 500 mg ööpäevas.
English: EU/1/13/870/004 [30 hard capsules] EU/1/13/870/005 [60 hard capsules] EU/1/13/870/006 [120 hard capsules]
Estonian: EU/1/13/870/004 [30 kõvakapslit] EU/1/13/870/005 [60 kõvakapslit] EU/1/13/870/006 [120 kõvakapslit]
English: No data on the effects of cholic acid on fertility are available.
Estonian: Andmed koolhappe toime kohta fertiilsusele puuduvad.
English: Cholic acid treatment results for seven patients with Δ4-3-Oxosteroid-5β-reductase deficiency for up to 14 years are reported in the literature.
Estonian: Kirjanduses on koolhappe kasutamise tulemused avaldatud 7 Δ4-3-oksüsteroid-5β-reduktaasi puudulikkusega patsiendi kohta, keda on jälgitud kuni 14 aastat.
English: Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency and no dose recommendation can be given.
Estonian: steroidi oksidoreduktaasi või Δ4-3-oksüsteroid-5β-reduktaasi puudulikkus, ja annuseid soovitada ei saa.
English: Treatment should be stopped earlier if there are clear indicators of severe hepatic failure.
Estonian: Kui ilmnevad selged raskekujulise maksapuudulikkuse nähud, tuleb ravi lõpetada varem.
English: Gelatin (bovine origin), Titanium dioxide (E171), Carmine blue (E132).
Estonian: Želatiin (veise päritolu) titaandioksiid (E171) karmiinsinine (E132).
English: EU/1/13/870/001 [30 hard capsules] EU/1/13/870/002 [60 hard capsules] EU/1/13/870/003 [120 hard capsules]
Estonian: EU/1/13/870/001 [30 kõvakapslit] EU/1/13/870/002 [60 kõvakapslit] EU/1/13/870/003 [120 kõvakapslit]
English: The remaining part is transformed by reduction of the 7α-hydroxy group to deoxycholic acid (3α, 12α-dihydroxy) by intestinal bacteria.
Estonian: Ülejäänud osa muundavad soolebakterid 7αhüdroksürühma redutseerimise teel desoksükoolhappeks (3α, 12α-dihüdroksü-5-β-kolaan-24karboksüülhape).
English: There is no need for contraceptive measures in women of childbearing potential treated with cholic acid or their partners.
Estonian: Rasestuda võivad naised ja nende partnerid ei pea koolhappe manustamise ajal kasutama rasestumisvastaseid vahendeid.
English: The objectives of this surveillance programme is to monitor accumulating data on efficacy and safety in the treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency with Orphacol in infants, children, adolescents and adults.
Estonian: Järelevalveprogrammi eesmärk on jälgida andmeid, mida kogutakse Orphacoli efektiivsuse ja ohutuse kohta 3β-hüdroksü-Δ5-C27-steroidi oksidoreduktaasi või Δ4-3
English: Each hard capsule contains 250 mg cholic acid.
Estonian: Üks kõvakapsel sisaldab 250 mg koolhapet.
English: Increased liver weight and gallstones have been reported in repeated dose studies in which cholic acid was co-administered with cholesterol.
Estonian: Korduvtoksilisuse uuringutes, kus koolhapet manustati koos kolesterooliga, täheldati maksa suurenemist ja sapikivide teket.
English: Gelatin (bovine origin), Titanium dioxide (E171), Carmine blue (E132), Yellow Iron Oxide (E172).
Estonian: Želatiin (veise päritolu) titaandioksiid (E171) karmiinsinine (E132) kollane raudoksiid (E172).
English: Orphacol 50 mg capsules Cholic acid
Estonian: Orphacol 50 mg kapslid Koolhape
English: Cholic acid This medicine is subject to additional monitoring.
Estonian: Koolhape Käesoleva ravimi suhtes kohaldatakse täiendavat järelevalvet, mis võimaldab kiiresti tuvastada uut ohutusteavet.
English: Orphacol 250 mg capsules Cholic acid
Estonian: Orphacol 250 mg kapslid Koolhape
English: Patients with newly diagnosed or a family history of familial hypertriglyceridemia are expected to poorly absorb cholic acid in the intestine.
Estonian: Familiaalse hüpertriglütserideemia esmakordse diagnoosiga patsientidel või haiguse esinemise korral perekonnas imendub koolhape sooles tõenäoliselt halvasti.
English: Each hard capsule contains 50 mg cholic acid.
Estonian: Üks kõvakapsel sisaldab 50 mg koolhapet.
English: No experience exists in patients with hepatic impairment from causes other than 3β
Estonian: Puudub kasutamise kogemus patsientidel, kelle maksakahjustuse põhjus on muu kui 3β-hüdroksü-Δ5-C27
English: See the package leaflet for further information.
Estonian: Vt lisateavet pakendi infolehelt.
English: Use of phenobarbital in patients with 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency treated with cholic acid is contraindicated (see section 4.3).
Estonian: oksüsteroid-5β-reduktaasi puudulikkusega patsientidel, keda ravitakse koolhappega, on fenobarbitaali kasutamine vastunäidustatud (vt lõik 4.3).
English: 3β, 7α, 12α-trihydroxy-5-cholenoic acids) or in Δ4-3-Oxosteroid-5β-reductase deficiency (3-oxo-7α-hydroxy- and 3-oxo-7α, 12α-dihydroxy-4-cholenoic acids) should be determined.
Estonian: Määrata tuleb 3β-hüdroksü-Δ5-C27-steroidi oksidoreduktaasi puudulikkuse või Δ4-3-oksüsteroid-5β-reduktaasi puudulikkuse korral sünteesitavate sapphappe ebatavaliste metaboliitide (vastavalt 3β, 7α-dihüdroksü- ja 3β, 7α, 12α-trihüdroksü-5koleenhapete ning 3-okso-7α-hüdroksü- ja 3-okso-7α, 12α-dihüdroksü-4-koleenhapete) kontsentratsioonid.
English: The concentrations of the abnormal bile acid metabolites synthesised in 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency (3β, 7α-dihydroxy- and
Estonian: Määrata tuleb 3β-hüdroksü-Δ5-C27-steroidi oksidoreduktaasi puudulikkuse (3β, 7α-dihüdroksü- ja 3β, 7α, 12α-trihüdroksü-5-koleenhapete) või Δ4-3
English: The usual starting dose is 5 to 15 mg per kilogram body weight every day in infants, children, adolescents and adults.
Estonian: Tavaline algannus imikutel, lastel, noorukitel ja täiskasvanutel on 5…15 mg kehakaalu kilogrammi kohta ööpäevas.
English: Patients with newly diagnosed or a family history of familial hypertriglyceridaemia may have poor absorption of cholic acid from the intestine.
Estonian: Perekondliku hüpertriglütserideemia esmakordse diagnoosiga patsientidel või haiguse esinemise korral perekonnas võib koolhape sooles halvasti imenduda.
English: Orphacol 250 mg hard capsules
Estonian: Orphacol 250 mg kõvakapslid
English: Deoxycholic acid is a secondary bile acid.
Estonian: Desoksükoolhape on teisene sapphape.
English: Orphacol 50 mg hard capsules
Estonian: Orphacol 50 mg kõvakapslid
English: No experience exists in patients with hepatic impairment from causes other than 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency and no dose recommendation can be given.
Estonian: steroidi oksidoreduktaasi või Δ4-3-oksüsteroid-5β-reduktaasi puudulikkusest ja soovitusi annuste kohta anda ei saa.
English: This summary was last updated in January-2013.
Estonian: Kokkuvõtte viimane uuendus: 01-2013.
English: The vaccine is given in the neck in the area behind the ear.
Estonian: Vaktsiin süstitakse kaela, kõrva taha.
English: The main measure of effectiveness was the percentage cumulative mortality (overall death rate) of the piglets.
Estonian: Efektiivsuse põhinäitaja oli põrsaste kumulatiivse kogusuremuse protsent.
English: Enterotoxicosis is a reaction in the intestines to toxins produced by some bacteria.
Estonian: Enterotoksikoos on sooleseina reaktsioon teatud bakterites tekkivatele toksiinidele.
English: It is a suspension for injection and contains the active substances F4ab, F4ac, F5, F6, and LT toxoid.
Estonian: Vaktsiini toimeained on F4ab, F4ac, F5, F6 ja LT-toksoid.
English: Porcilis Porcoli Diluvac Forte is used to immunise against E. coli which have the adhesins (surface components) F4ab (K88ab), F4ac (K88ac), F5 (K99) or F6 (987P).
Estonian: Vaktsiini Porcilis Porcoli Diluvac Forte kasutatakse adhesiinidega (pinnakomponendid) F4ab (K88ab), F4ac (K88ac), F5 (K99) või F6 (987P) E. coli tüvede vastaseks vaktsineerimiseks.
English: The vaccine (or parts of the vaccine) has been studied in several trials in pregnant pigs of various breeds.
Estonian: Vaktsiini (või selle osi) uuriti mitmes eri tõugu tiinetel emistel toimunud uuringus.
English: It is preferable to vaccinate female pigs during the second half of their pregnancy, but not within two weeks before the expected date of farrowing.
Estonian: Emiseid on eelistatav vaktsineerida tiinuse teises pooles, kuid mitte hiljem kui kaks nädalat enne eeldatavat poegimist.
English: These pigs were given two injections of the vaccine and then the litters of these pigs, as well as litters where the mother had not been vaccinated (controls), were exposed to E. coli containing the adhesins or LT toxin present in the vaccine.
Estonian: Uuringurühma sigadele tehti kaks vaktsiinisüsti ja seejärel tekitati nende sigade põrsastel ning ka vaktsineerimata emiste põrsastel (kontrollrühm) kokkupuude E. coli bakteritega, millel olid vaktsiinis sisalduvad adhesiinid või LT-toksiin.
English: Female pigs that have not been vaccinated should be given two injections with an interval of six weeks between them.
Estonian: Vaktsineerimata emistele peab 6-nädalase vahega manustama kaks süstet.
English: Porcilis Porcoli Diluvac Forte reduced the death rate in all the studies when compared with the control piglets.
Estonian: Porcilis Porcoli Diluvac Forte vähendas kõikides uuringutes suremust võrreldes kontrollrühma põrsastega.
English: To maintain the immunity, a single injection should be given before each subsequent farrowing (giving birth to the piglets).
Estonian: Immuunsuse säilitamiseks tuleb iga järgneva poegimise eel teha üks süst.
English: Porcilis Porcoli Diluvac Forte can cause mild, temporary clinical reactions (fever, lethargy, reduced food intake) during the first 24 hours after vaccination.
Estonian: Porcilis Porcoli Diluvac Forte võib esimese 24 vaktsineerimisjärgse tunni jooksul põhjustada kergeid ajutisi kliinilisi reaktsioone (palavik, letargia, söögiisu vähenemine).
English: There may be redness and/or a swelling at the injection site, for up to 2 weeks after vaccination.
Estonian: Samuti võib kuni 2 nädala jooksul pärast vaktsineerimist tekkida süstekohal punetus ja/või turse.
English: When the sow is injected, this small exposure helps the pig's immune system to recognise and attack the E. coli bacteria.
Estonian: Emiste süstimisel satuvad need sea organismi ja see vähene kokkupuude aitab sea immuunsüsteemil edaspidi E. coli bakteri ära tunda ning sellega võidelda.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Porcilis Porcoli Diluvac Forte to Intervet International B.V. on 2 May 2002.
Estonian: Euroopa Komisjon andis vaktsiini Porcilis Porcoli Diluvac Forte müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Intervet International B.V.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) agreed that the benefits of Porcilis Porcoli Diluvac Forte, to reduce death and clinical signs of enterotoxicosis caused by E. coli bacteria, are greater than any risks.
Estonian: Veterinaarravimite komitee järeldas, et vaktsiini Porcilis Porcoli Diluvac Forte kasulikkus bakteri E. coli tekitatud enterotoksikoosist põhjustatud surma ja kliiniliste nähtude vähendamisel on suurem kui kaasnevad riskid.
English: Porcilis Porcoli Diluvac Forte contains adhesins that are found on the surface of E. coli bacteria.
Estonian: Porcilis Porcoli Diluvac Forte sisaldab E. coli bakteri pinnal olevaid adhesiine.
English: Porcilis Porcoli Diluvac Forte is a vaccine for use in pigs.
Estonian: Porcilis Porcoli Diluvac Forte on sigade vaktsiin.
English: They recommended that Porcilis Porcoli Diluvac Forte should be given a marketing authorisation.
Estonian: Vaktsiinile Porcilis Porcoli Diluvac Forte soovitati anda müügiluba.
English: Porcilis Porcoli Diluvac Forte is used to reduce death and clinical signs of enterotoxicosis caused by E. coli bacteria in piglets during the first days of their life.
Estonian: Vaktsiini Porcilis Porcoli Diluvac Forte kasutatakse põrsaste vaktsineerimiseks, et vähendada E. coli bakterite põhjustatavast enterotoksikoosist tingitud suremist ja selle kliinilisi nähte esimestel elupäevadel.
English: Why has Porcilis Porcoli Diluvac Forte been approved?
Estonian: Miks Porcilis Porcoli Diluvac Forte heaks kiideti?
English: Other information about Porcilis Porcoli Diluvac Forte:
Estonian: Muu teave vaktsiini Porcilis Porcoli Diluvac Forte kohta
English: Porcilis Porcoli Diluvac Forte is given as a dose of 2 ml by intramuscular (into a muscle) injection to female pigs.
Estonian: Vaktsiini Porcilis Porcoli Diluvac Forteis manustatakse 2 ml annuses lihasesisese süstena emistele.
English: How has the effectiveness of Porcilis Porcoli Diluvac Forte been studied?
Estonian: Kuidas vaktsiini Porcilis Porcoli Diluvac Forte efektiivsust uuriti?
English: This immunity is passed onto the sow's piglets through her colostrum.
Estonian: Nende põrsad omandavad immuunsuse ternespiimaga.
English: What is Porcilis Porcoli Diluvac Forte?
Estonian: Mis on Porcilis Porcoli Diluvac Forte?
English: How does Porcilis Porcoli Diluvac Forte work?
Estonian: Kuidas Porcilis Porcoli Diluvac Forte toimib?
English: What are the side effects of Porcilis Porcoli Diluvac Forte?
Estonian: Mis riskid vaktsiiniga Porcilis Diluvac Forte Porcoli kaasnevad?
English: What is Porcilis Porcoli Diluvac Forte used for?
Estonian: Milleks vaktsiini Porcilis Porcoli Diluvac Forte kasutatakse?
English: What benefit has Porcilis Porcoli Diluvac Forte shown during the studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini Porcilis Porcoli Diluvac Forte kasulikkus?
English: • Risk Management Plan (RMP) Not applicable.
Estonian: • Riskijuhtimiskava (RMP) Ei kohaldata.